Page 133 - Demo

Outcomes and outcome measurement instruments1315References1. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health Qual Life Outcomes. 2006;4. 2. Churruca K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LED, et al. Patient-reported outcome measures (PROMs): A review of generic and condition-specific measures and a discussion of trends and issues. Vol. 24, Health Expectations. 2021. 3. Valderas JM, Alonso J. Patient reported outcome measures: A model-based classification system for research and clinical practice. Qual Life Res. 2008;17(9). 4. FDA Clinical Outcome Assessments [Internet]. [cited 2023 Jul 11]. Available from: https://www.fda.gov/about-fda/cdrh-patient-science-and-engagement-program/clinical-outcomeassessments-coas-medical-device-decision-making.5. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. Arlington. 2013. 6. Leonard H, Wen X. The epidemiology of mental retardation: Challenges and opportunities in the new millennium. Vol. 8, Mental Retardation and Developmental Disabilities Research Reviews. 2002. 7. Pinchefsky E, Shevell M. Intellectual Disabilities and Global Developmental Delay. In: Handbook of DSM-5 Disorders in Children and Adolescents. 2017. 8. Kvarnung M, Nordgren A. Intellectual disability & rare disorders: A diagnostic challenge. In: Advances in Experimental Medicine and Biology. 2017. 9. Wang J, Wang Y, Wang L, Chen WY, Sheng M. The diagnostic yield of intellectual disability: Combined whole genome low-coverage sequencing and medical exome sequencing. BMC Med Genomics. 2020;13(1). 10. Pekeles H, Accogli A, Boudrahem-Addour N, Russell L, Parente F, Srour M. Diagnostic Yield of Intellectual Disability Gene Panels. Pediatr Neurol. 2019;92. 11. Castrén E, Elgersma Y, Maffei L, Hagerman R. Treatment of Neurodevelopmental disorders in Adulthood. J Neurosci. 2012;32(41). 12. Levy G, Barak B. Postnatal therapeutic approaches in genetic neurodevelopmental disorders. 3:2021. Available from: https://doi.org/10.4103/1673-5374.293133.13. Ferrari M. Borderline intellectual functioning and the intellectual disability construct. Vol. 47, Intellectual and Developmental Disabilities. 2009. 14. Swillen A, McDonald-Mcginn D. Developmental trajectories in 22q11.2 deletion syndrome. Am J Med Genet Part C Semin Med Genet. 2015;169(2). 15. Green Snyder LA, D’Angelo D, Chen Q, Bernier R, Goin-Kochel RP, Wallace AS, et al. Autism Spectrum Disorder, Developmental and Psychiatric Features in 16p11.2 Duplication. J Autism Dev Disord. 2016;46(8). 16. Cannizzo S, Lorenzoni V, Palla I, Pirri S, Trieste L, Triulzi I, et al. Rare diseases under different levels of economic analysis: Current activities, challenges and perspectives. Vol. 4, RMD Open. 2018. 17. Walton MK, Powers JH, Hobart J, Patrick D, Marquis P, Vamvakas S, et al. Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes AssessmentEmerging Good Practices for Outcomes Research Task Force. Value Heal. 2015;18(6). 18. Gnanasakthy A, Qin S, Norcross L. FDA Guidance on Selecting, Developing, or Modifying Fitfor-Purpose Clinical Outcome Assessments: Old Wine in a New Bottle? Vol. 16, Patient. 2023. 19. Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): Current perspectives. Therapeutics and Clinical Risk Management. 2019. 20. Van Eeghen AM, Bruining H, Wolf NI, Bergen AA, Houtkooper RH, Van Haelst MM, et al. Personalized medicine for rare neurogenetic disorders: can we make it happen? Cold Spring Harb Mol Case Stud. 2022;8(2):a006200. Annelieke Muller sHL.indd 131 14-11-2023 09:07